Inhibition of LOX in invasive lobular carcinoma intraductal xenografts

Background: Invasive lobular carcinoma (ILC) has previously been identified as overexpressing collagens and elastin as well as LOXL1, a collagen cross-linking enzyme belonging to the lysly oxidase (LOX) family. Aberrant LOX activity can promote breast cancer invasion and metastasis through remodelling of the extracellular matrix (ECM). We propose that inhibition of LOX be investigated as a therapeutic strategy in the treatment of ILC.Methods: We xenograft ILC cells into the milk ducts of mice (MIND) to faithfully recapitulate ILC disease progression including ECM remodelling processes. We used cell line and PDX MIND models of ILC to examine their response to LOX inhibition (LOXi) alone and combination with ovariectomy (OVX) to mimic aromatase inhibition (AI).